DNTH

+ Watchlist + Portfolio

Dianthus Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $113.70
52-Week Range: $22.76 – $117.88
Market Cap: $6.13B
P/E (TTM): —
EPS (TTM): -4.24
Dividend Yield: —

Advanced Metrics

Price/Book: 5.12
PEG Ratio: —
Return on Equity: -26.06%
Return on Assets: -17.69%
Gross Margin: 100.00%
Operating Margin: -8079.11%
Profit Margin: 0.00%
Current Ratio: 26.10
Debt/Equity: 0.00
Total Debt: $1.29M
Free Cash Flow: $-92.21M
Revenue Growth: 294.30%
Earnings Growth: —
Enterprise Value: $5.47B

DNTH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.42M	$2.83M	$6.24M	$2.04M
Research & Development	$29.38M	$32.84M	$83.11M	$145.64M
Selling, General & Admin	$6.74M	$18.16M	$24.99M	$34.33M
Operating Expenses	$36.12M	$51.00M	$108.10M	$179.97M
Operating Income	-$29.70M	-$48.17M	-$101.86M	-$177.93M
EBITDA	-$29.56M	-$47.82M	-$101.45M	-$177.50M
Pretax Income	-$28.48M	-$43.55M	-$84.97M	-$162.34M
Net Income	-$28.48M	-$43.55M	-$84.97M	-$162.34M
Diluted EPS	-1.92	-8.45	-2.55	-4.20
Diluted Shares	14.82M	5.15M	33.31M	38.62M

DNTH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$15.37M	$132.32M	$22.79M	$51.09M
Receivables	$5.64M	$478.00K	$807.00K	$52.00K
Current Assets	$82.03M	$177.45M	$280.90M	$409.44M
Total Assets	$83.11M	$179.41M	$374.01M	$530.92M
Current Liabilities	$8.22M	$9.63M	$18.45M	$30.73M
Total Debt	$788.00K	$585.00K	$1.49M	$1.39M
Total Liabilities	$9.45M	$10.54M	$21.53M	$37.52M
Retained Earnings	-$45.87M	-$89.42M	-$174.39M	-$336.73M
Shareholders' Equity	$73.66M	$168.87M	$352.48M	$493.40M
Working Capital	$73.81M	$167.82M	$262.45M	$378.71M

DNTH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.07M	-$36.86M	-$78.18M	-$129.06M
Capital Expenditure	-$139.00K	-$110.00K	-$105.00K	-$213.00K
Free Cash Flow	-$29.21M	-$36.97M	-$78.28M	-$129.27M
Depreciation & Amortisation	$147.00K	$355.00K	$412.00K	$428.00K
Stock-Based Compensation	$1.52M	$2.90M	$12.89M	$22.79M
Investing Cash Flow	-$59.82M	$20.25M	-$286.81M	-$122.83M
Financing Cash Flow	$96.68M	$133.57M	$255.62M	$280.13M
Net Change in Cash	$7.79M	$116.97M	-$109.37M	$28.23M

DNTH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.16M	$193.00K	$396.00K	$284.00K	$463.00K
Research & Development	$27.00M	$26.25M	$32.49M	$59.90M	$34.53M
Selling, General & Admin	$7.34M	$8.87M	$8.20M	$9.93M	$12.47M
Operating Expenses	$34.34M	$35.12M	$40.68M	$69.83M	$47.00M
Operating Income	-$33.18M	-$34.93M	-$40.29M	-$69.54M	-$46.53M
EBITDA	-$33.04M	-$34.83M	-$40.19M	-$69.44M	-$46.46M
Pretax Income	-$29.51M	-$31.63M	-$36.77M	-$64.43M	-$40.83M
Net Income	-$29.51M	-$31.63M	-$36.77M	-$64.43M	-$40.83M
Diluted EPS	-0.82	-0.88	-0.97	-1.43	-0.85
Diluted Shares	35.79M	35.82M	37.79M	44.97M	48.03M

DNTH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.12M	$13.24M	$55.98M	$51.09M	$627.67M
Receivables	$1.00M	$39.00K	$5.00M	$52.00K	$1.23M
Current Assets	$271.00M	$263.61M	$413.82M	$409.44M	$1.12B
Total Assets	$348.58M	$326.08M	$577.45M	$530.92M	$1.25B
Current Liabilities	$16.95M	$20.09M	$23.86M	$30.73M	$38.28M
Total Debt	$1.40M	$1.33M	$1.28M	$1.39M	$1.36M
Total Liabilities	$19.97M	$23.00M	$30.99M	$37.52M	$45.57M
Retained Earnings	-$203.90M	-$235.53M	-$272.30M	-$336.73M	-$377.56M
Shareholders' Equity	$328.61M	$303.08M	$546.45M	$493.40M	$1.20B
Working Capital	$254.05M	$243.51M	$389.97M	$378.71M	$1.08B

DNTH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$27.63M	-$23.89M	-$30.55M	-$46.98M	-$28.86M
Capital Expenditure	-$24.00K	-$46.00K	-$5.00K	-$138.00K	-$10.00K
Free Cash Flow	-$27.65M	-$23.94M	-$30.56M	-$47.12M	-$28.87M
Depreciation & Amortisation	$133.00K	$99.00K	$99.00K	$97.00K	$76.00K
Stock-Based Compensation	$5.32M	$5.71M	$5.79M	$5.98M	$10.60M
Investing Cash Flow	$14.79M	$26.45M	-$201.28M	$37.20M	-$133.97M
Financing Cash Flow	$161.00K	$568.00K	$274.51M	$4.88M	$739.41M
Net Change in Cash	-$12.68M	$3.12M	$42.68M	-$4.90M	$576.58M

Market Snapshot

About

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for complement-mediated autoimmune and inflammatory diseases. The company's lead program targets rare diseases where the complement system, a part of the immune system, causes tissue damage. Dianthus is advancing therapies designed to selectively inhibit specific components of the complement cascade. The company's pipeline addresses significant unmet medical needs in conditions with limited treatment options.